Richard spent 25 years in senior roles as an equity analyst covering the pharmaceutical and biotechnology industries at multiple investment banks, including BNP Paribas Exane, Deutsche Bank, Piper Jaffray and ING Financial Markets.  During this time, he developed an extensive knowledge of industry pipelines and an ability to critically appraise and value innovation. He has subsequently been highly ranked in the Institutional Investor and Extel surveys and been involved in initial public offerings for multiple biotechnology and pharmaceutical companies. Richard is now acting as a consultant and holds a senior advisory position at Brunswick Group. Richard gained his PhD in Molecular Genetics from the Liverpool School of Tropical Medicines and subsequently conducted postdoctoral research in gene therapy at the Institute of Child Health, UCL, London.